Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the foundation for pivotal development, backed by FDA and EMA endorsements in early 2025. The manufactur
